Tus kws kho mob
P47-17 Change to the Requirement to Submit National Drug Codes
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 23, 2017
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 2801 - 2810 ntawm 4179
Tus kws kho mob
P36-16 Case Management (T1016) Billing for Tuberculosis Related Services for Government Programs Subscribers
Hnub Tim pib siv tau lub khoos kas: Lub Xya Hli Ntuj Tim 27, 2016
Tus kws kho mob
P60-16 New Drug-Related Prior Authorization Criteria with Quanatity Limit for Topical Diclofenac Gel, Fluorourcil Cream, Imquimod Cream and Ingenol Gel
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ob Hlis Ntuj Tim 13, 2016
Tus kws kho mob
P39-16 Expansion of Drug-Related Xenazine Prior Authorization Criteria with Quantity Limit to Minnesota Health Care Programs
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 03, 2016
Tus kws kho mob
P40-16 New Drug-Related Prior Authorization Criteria with Quantity Limit for Lidocaine Transdermal
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 03, 2016
Tus kws kho mob
P45R1-16 Update on New Drug, Ocrevus (ocrelizumab)
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ob Hlis Ntuj Tim 05, 2016
Tus kws kho mob
P45-16 A New Drug, Ocrevus (ocrelizumab) Will Require Prior Authorization
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ob Hlis Ntuj Tim 05, 2016
Tus kws kho mob
P57-16 Change in Medical Policy and Commercial Benefit Coverage of CT Colonography Colorectal Cancer Screening Test
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 22, 2016
Tus kws kho mob
P37-16 Addition of a Drug (Epclusa) to the Hepatitis C Second Generation Prior Authorization with Quantity Limit Program
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 03, 2016
Tus kws kho mob
P24-17 AOR No Longer Required for Submission of Organization Determinations for Platinum Blue Subscribers
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 18, 2017